Berenberg analyst Luisa Hector raised the firm’s price target on AstraZeneca (AZN) to $97 from $93 and keeps a Buy rating on the shares. The firm increased its 2030 revenue forecast by 3% to $79B, ahead of consensus, saying the company has seen “substantial pipeline progress already this year.” AstraZeneca shares should price in a larger pipeline valuation, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s Ondexxya Study: A Closer Look at Safety and Effectiveness
- AstraZeneca’s NASH Study Completes: Market Implications of AZD4831
- AstraZeneca’s Latest Study on Inhaler Propellants: Key Insights for Investors
- AstraZeneca’s Real-World Study on Dapagliflozin: A Strategic Move in Heart Failure Treatment
- AstraZeneca’s SERENA-1 Study: A Promising Development in Breast Cancer Treatment